整合不同的观点来定义一种综合性缓解的概念在类风湿性关节炎:SUMAR项目
Alejandro Balsa1, José Luis Andreu2, Juan Carlos Hermosa-Hernán3
1Rheumatology Unit, Hospital Universitario La Paz, Instituto de Investigación IdiPAZ, Madrid, Spain.
Reumatologia clinica
|February 2, 2025
概括
一个新的共识定义了类风湿性关节炎的缓解超出了炎症,包括患者报告的疼痛和功能. 这种综合性方法旨在改善类风湿性关节炎患者的生活质量.
科学领域:
- 类风湿病学 类风湿病学
- 医疗保健服务研究 医疗服务研究
- 患者报告的结果
背景情况:
- 类风湿性关节炎 (RA) 缓解的概念传统上集中在炎症标志物上.
- 在不同利益关方 (患者,医疗保健专业人员,管理人员) 之间就缓解问题达成共识是具有挑战性的.
- 现有的定义可能无法完全捕捉RA缓解的患者体验.
研究的目的:
- 建立关于类风湿性关节炎 (RA) 缓解的定义的共识.
- 将患者,医疗保健专业人员和医疗保健管理人员的观点纳入RA缓解的定义.
- 开发一个全面的缓解概念,包括临床和以患者为中心的结果.
主要方法:
- 一个多阶段项目 (2020-2021年) 涉及科学委员会组成和利益相关方参与.
- 第一个阶段:对275名患者,160名风湿病学家和31名管理人员的RA缓解前景的分析.
- 第二阶段和第三阶段:通过多学科研讨会和多达200名参与者参加的区域会议进行综合性定义开发.
主要成果:
- 利益相关者对RA缓解的看法最初是异质的.
- 达成协议,将疼痛,功能和持续时间与炎症活动一起纳入缓解的定义.
- 实施全面缓解概念的障碍包括咨询时间和IT系统的变化.
结论:
- 缓解的发展定义超出了仅仅是炎症活动的范围.
- 它包含了患者报告的变量,这些变量对健康和生活质量至关重要.
- 这种以患者为中心的定义增强了对缓解在类风湿性关节炎护理中的理解和应用.
相关概念视频
Genome-wide Association Studies-GWAS
12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.4K
Inflammatory Response
1.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.8K
T Cell Types and Functions
939
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
939
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100


